We've curated a special 10-minute version of the podcast for those in a hurry. Here you can listen to the full episode: https://podcasts.apple.com/no/podcast/gsk-ceo-drug-discovery-ai-in-pharma-and-changing/id1614211565?i=1000701828482&l=nbHow is the pharmaceutical industry evolving to meet the world’s biggest health challenges? In this episode, Nicolai Tangen sits down with Emma Walmsley, CEO of GSK, for an insightful conversation about the future of pharmaceuticals. They discuss GSK’s latest advances in cancer treatments, HIV therapies, and respiratory medicine, as well as the role of AI in speeding up drug discovery. Emma also shares her thoughts on navigating change, transforming company culture, and the role of curiosity in staying motivated. Tune in!In Good Company is hosted by Nicolai Tangen, CEO of Norges Bank Investment Management. New full episodes every Wednesday, and don't miss our Highlight episodes every Friday.The production team for this episode includes Isabelle Karlsson and PLAN-B's Niklas Figenschau Johansen, Sebastian Langvik-Hansen and Pål Huuse. Background research was conducted by Isabelle Karlsson.Watch the episode on YouTube: Norges Bank Investment Management - YouTubeWant to learn more about the fund? The fund | Norges Bank Investment Management (nbim.no)Follow Nicolai Tangen on LinkedIn: Nicolai Tangen | LinkedInFollow NBIM on LinkedIn: Norges Bank Investment Management: Administrator for bedriftsside | LinkedInFollow NBIM on Instagram: Explore Norges Bank Investment Management on Instagram Hosted on Acast. See acast.com/privacy for more information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related